Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 504 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing MOST POPULAR ΚΑΡΚΙΝΟΣ ΠΑΧΕΩΣ ΕΝΤΕΡΟΥ February 10, 2019 37-Year-Old Mom Breaks American Marathon Record January 21, 2022 FDA Approves Crizotinib for Children and Young Adults with Relapsed or... January 19, 2021 Prising open the trap: Getting to grips with targeted cancer drug... January 10, 2022 Load more HOT NEWS Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal... Opdualag Becomes First FDA-Approved Immunotherapy to Target LAG-3 Epigenetic Changes Pinpointed as the Cause of Some GISTs Long-Term Clinical Benefit with Nivolumab Plus Ipilimumab Extends Beyond Treatment Discontinuation...
